Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? an umbrella review of published meta-analyses
Mohammed I Danjuma, Rana Sayed, Maryam Aboughalia, Aseel Hassona, Basant Selim Elsayed, Mohamed Elshafei, Abdelnaser Elzouki, Dr Mohammed Ibn-Mas'ud Danjuma, New York, Doha Qatar
Background Despite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Covid-19 clinical syndrome.
Methods: In this umbrella review, we carried out a comprehensive search of PubMed, EMBASE, Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of Abstracts of Reviews of Effectiveness between 1st January 2020 and 31st January 2023 for systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine in patients with Covid-19. This was to ascertain the exact relationship between colchicine exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality and risk of bias assessment of the included reviews.
Results: We included eighteen meta-analyses (n = 199,932 participants) in this umbrella review. Colchicine exposure was associated with an overall reduction of about 35% in the risk of mortality (odds ratio 0.68, confidence interval [CI] 0.58-0.78; I2 = 94%, p = 0.001). Further examination of pooled estimates of mortality outcomes by the quality effects model (corrected for the methodological quality and risk of bias of the constituent reviews) reported similar point estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%).
Conclusion: In a pooled umbrella evaluation of published meta-analyses of Covid-19 patient cohorts, exposure to colchicine was associated with a reduction in overall mortality. Although it remains uncertain if this effect could potentially be attenuated or augmented by Covid-19 vaccination.
Not applicable
Included Records excluded (n = 67) Wrong outcome (30) Wrong study design (15) Wrong population (22) Records screened (n = 106) Full This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4447127 P r e p r i n t n o t p e e r r e v i e w e d
References
Beck, Shin, Choi, Park, Kang, Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Comput Struct Biotechnol J
Bhimraj, Morgan, Shumaker, Lavergne, Baden et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, Clin Infect Dis
Bitar, Sulaiman, The evidence from clinical trials on colchicine and corticosteroids' effect on COVID-19: a systematic review and meta-analysis, Curr Med Res Opin
Bonaventura, Vecchié, Dagna, Tangianu, Abbate et al., Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
Cheng, Zhao, Chen, Jia, Fang, Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network metaanalysis of 48 randomized controlled trials, Medicine (United States)
Chiu, Lo, Shen, Chiu, Aggarwal et al., Colchicine use in patients with COVID-19: A systematic review and meta-analysis, PLoS One
Crichton, Goeminne, Tuand, Vandendriessche, Tonia et al., The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline, European Respiratory Review
Cruciani, Amato, De Crescenzo, Mitrova, Saulle et al., L'elogio dell'incertezza: una revisione sistematica living per valutare l'efficacia e la sicurezza dei trattamenti farmacologici per pazienti affetti da covid-19, Recenti Prog Med
Danjuma, Kaul, Alyaarabi, Elsayed, Elshafei, Colchicine and mortality outcomes in patients with coronavirus disease (COVID-19), Eur J Intern Med,
doi:10.1016/j.ejim.2023.02.009De-Miguel-Balsa E, Estevan-Ortega R, Sempere-Selva Mt, Latour-Pérez J, Baeza-Román A, Moya-Martinez, Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis, Eur Rev Med Pharmacol Sci
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents
Elfiky, Anti-HCV, nucleotide inhibitors, repurposing against COVID-19, Life Sci
Elfiky, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study, Life Sci
Elshafei, El-Bardissy, Khalil, Danjuma, Mubasher et al., Colchicine use might be associated with lower mortality in COVID-19 patients: A metaanalysis, Eur J Clin Invest
Elshafei, El-Bardissy, Khalil, Danjuma, Mubasher et al., Colchicine use might be associated with lower mortality in COVID-19 patients: A metaanalysis, Eur J Clin Invest
Golpour, Mousavi, Alimohammadi, Mosayebian, Shiran et al., The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis, Int J Immunopathol Pharmacol
Gordon, Jang, Bouhaddou, Xu, Obernier et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature
Group, Mikolajewska, Fischer, Piechotta, Mueller et al., Colchicine for the treatment of COVID-19, Cochrane Database of Systematic Reviews
Han, Lee, Yoon, Nam, Ryu et al., Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials, Theranostics
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol
Kow, Lee, Ramachandram, Hasan, Ming et al., The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials. Immun Inflamm Dis
Lan, Hsu, Lai, Chang, Lu et al., Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials, Ann Med
Lien, Lee, Weng, Lin, Liu et al., Repurposing colchicine in treating patients with covid-19: A systematic review and meta-analysis, Life
Lin, Colchicine May Interfere With the Efficacy of the Adenoviral Vector-Based Vaccine for COVID-19, Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
Moher, Liberati, Tetzlaff, Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, J Clin Epidemiol
Nawangsih, Kusmala, Rakhmat, Handayani, Juliastuti et al., Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression, Int Immunopharmacol
Park, Kaur, Malhotra, Vij, Myocarditis after COVID-19 mRNA vaccination: A systematic review of case reports and case series, Clin Cardiol
Perricone, Scarsi, Brucato, Pisano, Pigatto et al., Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial, Eur J Intern Med
Polack, Thomas, Kitchin, Absalon, Gurtman et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Reyes, Hu, Teperman, Wampler Muskardin, Tardif et al., Antiinflammatory therapy for COVID-19 infection: The case for colchicine, Annals of the Rheumatic Diseases
Romeo, Barbagelata, Chiabrando, Damonte, Moras et al., The Effect of Colchicine on Mortality, Mechanical Ventilation, and Length of Stay in Patients with COVID-19 Infection: An Updated Systematic Review and Meta-analysis of Randomized Clinical Trials, Am J Ther
Salah, Mehta, Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19, American Journal of Cardiology
Sanghavi, Bansal, Kaur, Mughal, Keshavamurthy et al., Impact of colchicine on mortality and morbidity in COVID-19: a systematic review, Ann Med
Shea, Grimshaw, Wells, Boers, Andersson et al., Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews, BMC Med Res Methodol
Shea, Reeves, Wells, Thuku, Hamel et al., AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both, BMJ
Singh, Parida, Lingaraju, Kesavan, Kumar et al., Drug repurposing approach to fight COVID-19, Pharmacological Reports
Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Tardif, Bouabdallaoui, Allier, Gaudet, Shah et al., Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Toro-Huamanchumo, Benites-Meza, Mamani-García, Bustamante-Paytan, Ae et al., Efficacy of colchicine in the treatment of COVID-19 patients: A systematic review and meta-analysis, J Clin Med
Vrachatis, Giannopoulos, Giotaki, Raisakis, Kossyvakis et al., Impact of colchicine on mortality in patients with COVID-19: A meta-analysis, Hellenic Journal of Cardiology
Walsh, Frenck, Falsey, Kitchin, Absalon et al., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A
Yasmin, Najeeb, Moeed, Hassan, Khatri et al., Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials, PLoS One
Zein, Raffaello, Effect of colchicine on mortality in patients with COVID-19 -A systematic review and meta-analysis, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
Zhang, Wen, Yin, Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Zhang, Wen, Yin, Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials
